Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP

Table 3

Summary of studies of single-cycle adjuvant BEP chemotherapy.

Study	Eligibility	Median follow-up (months)	N	Number of malignant relapses (all relapses)	Predicted relapse risk	Predicted number of relapses
Gilbert (RMH) [20]	1 or 2 MRC RF	120	22	0 (1)	20%	4
Westermann (Switzerland) [21]	VI+; >50% EC	99	13; 29	1	30%	13
Albers (GCSCG) [23]	Any	56	191	1 (2)	26%	50
Tandstad [24] (SWENOTECA)	VI+; VI−	95	258; 255	7 (8); 3 (4)	42%; 12%	108; 31
111 study [25]	VI+	40	236	4 (7)	42%	99
Total			1004	16 (23)1.6% (2.3%)

23/305 equals 7.5% of predicted relapses.